Bristol Myers Squibb's Iza-Bren cuts risk of progression or death by 59% in Phase 3 breast cancer trial
Bitget2026/10/23 11:31- Bristol Myers Squibb reported iza-bren outperformed chemotherapy in the Phase 3 PANKU-Breast01 breast cancer trial, reducing disease progression or death.
- The trial enrolled patients with advanced HR-positive, HER2-negative breast cancer whose disease had progressed despite prior chemotherapy.
- Safety was manageable, with no new safety signals identified; few patients discontinued treatment because of treatment-related adverse events.
- Results will be presented at ESMO 2026, running October 23-27 in Madrid, with simultaneous publication in The Lancet.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Apple plans to raise 7 billions USD to repurchase stocks, returning to the US dollar bond market after a year and a half.
Apple raised approximately $7 billion through this bond issuance, which is divided into seven tranches with maturities ranging from two to ten years. The longest tranche was initially priced at a spread of 80 basis points over US Treasuries. The proceeds from the bonds will be used for general corporate purposes, including stock buybacks, dividend payments, and capital expenditures. Analysts pointed out that shareholder returns are a higher priority than AI capital expenditures in Apple's capital allocation.
BUZZ - Sun Life Financial shares fall after Q3 earnings release
Pegasystems Wins 10-Year U.S. Army Contract Worth Up to $419 Million
BUZZ - Coffee chain Dutch Bros shares fall due to weak sales outlook
Crypto prices
More
